Tags

Type your tag names separated by a space and hit enter

Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
J Pharmacol Exp Ther. 2010 Apr; 333(1):218-27.JP

Abstract

Prepulse inhibition (PPI) is a measure of sensorimotor gating and an endophenotype of schizophrenia. We have shown previously in rats that estrogen treatment prevents disruption of PPI by the 5-HT(1A)/5-HT(7) receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT). The aim of the present study was to examine the role of dopamine D(1) and D(2) and serotonin 5-HT(1A), 5-HT(2A), and 5-HT(7) receptors in these effects. Part 1 of this study investigated the ability of estrogen treatment to reverse PPI disruption induced by 8-OH-DPAT or the dopamine D(1)/D(2) receptor agonist apomorphine. Part 2 of this study compared these effects to the ability of various antagonists in reversing the action of 8-OH-DPAT and apomorphine on PPI. Female Sprague-Dawley rats were ovariectomized (OVX), and, where appropriate, they received silastic implants containing either a low (E20) or high dose (E100) of estrogen. Two weeks later, PPI was assessed using automated startle boxes. The disruption of PPI by either treatment with 8-OH-DPAT (0.5 mg/kg) or apomorphine (0.3 mg/kg) was similarly prevented by E100 treatment. 8-OH-DPAT-induced PPI disruption was reversed by pretreatment with the 5-HT(1A) receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate salt (WAY 100,635; 1 mg/kg) and the typical antipsychotic and dopamine D(2) receptor antagonist haloperidol (0.25 mg/kg), but it was not reversed by pretreatment with the dopamine D(1) receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH 23390; 0.1 mg/kg), the 5-HT(2A/2C) receptor antagonist ketanserin (2 mg/kg), or the 5-HT(7) receptor antagonist SB-269970 (10 mg/kg). Apomorphine-induced disruptions of PPI were reversed by haloperidol and SCH 23390 only. Estrogen may prevent disruptions of PPI induced by both 8-OH-DPAT and apomorphine by an action on dopamine D(2) receptors downstream of 5-HT(1A) receptors.

Authors+Show Affiliations

Behavioral Neuroscience Laboratory, Mental Health Research Institute, 155 Oak St., Parkville (Melbourne), Victoria 3052, Australia.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20042529

Citation

Gogos, Andrea, et al. "Estrogen Treatment Blocks 8-hydroxy-2-dipropylaminotetralin- and Apomorphine-induced Disruptions of Prepulse Inhibition: Involvement of Dopamine D1 or D2 or Serotonin 5-HT1A, 5-HT2A, or 5-HT7 Receptors." The Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 1, 2010, pp. 218-27.
Gogos A, Kwek P, Chavez C, et al. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. J Pharmacol Exp Ther. 2010;333(1):218-27.
Gogos, A., Kwek, P., Chavez, C., & van den Buuse, M. (2010). Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. The Journal of Pharmacology and Experimental Therapeutics, 333(1), 218-27. https://doi.org/10.1124/jpet.109.162123
Gogos A, et al. Estrogen Treatment Blocks 8-hydroxy-2-dipropylaminotetralin- and Apomorphine-induced Disruptions of Prepulse Inhibition: Involvement of Dopamine D1 or D2 or Serotonin 5-HT1A, 5-HT2A, or 5-HT7 Receptors. J Pharmacol Exp Ther. 2010;333(1):218-27. PubMed PMID: 20042529.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. AU - Gogos,Andrea, AU - Kwek,Perrin, AU - Chavez,Carolina, AU - van den Buuse,Maarten, Y1 - 2009/12/30/ PY - 2010/1/1/entrez PY - 2010/1/1/pubmed PY - 2010/4/23/medline SP - 218 EP - 27 JF - The Journal of pharmacology and experimental therapeutics JO - J Pharmacol Exp Ther VL - 333 IS - 1 N2 - Prepulse inhibition (PPI) is a measure of sensorimotor gating and an endophenotype of schizophrenia. We have shown previously in rats that estrogen treatment prevents disruption of PPI by the 5-HT(1A)/5-HT(7) receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT). The aim of the present study was to examine the role of dopamine D(1) and D(2) and serotonin 5-HT(1A), 5-HT(2A), and 5-HT(7) receptors in these effects. Part 1 of this study investigated the ability of estrogen treatment to reverse PPI disruption induced by 8-OH-DPAT or the dopamine D(1)/D(2) receptor agonist apomorphine. Part 2 of this study compared these effects to the ability of various antagonists in reversing the action of 8-OH-DPAT and apomorphine on PPI. Female Sprague-Dawley rats were ovariectomized (OVX), and, where appropriate, they received silastic implants containing either a low (E20) or high dose (E100) of estrogen. Two weeks later, PPI was assessed using automated startle boxes. The disruption of PPI by either treatment with 8-OH-DPAT (0.5 mg/kg) or apomorphine (0.3 mg/kg) was similarly prevented by E100 treatment. 8-OH-DPAT-induced PPI disruption was reversed by pretreatment with the 5-HT(1A) receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate salt (WAY 100,635; 1 mg/kg) and the typical antipsychotic and dopamine D(2) receptor antagonist haloperidol (0.25 mg/kg), but it was not reversed by pretreatment with the dopamine D(1) receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH 23390; 0.1 mg/kg), the 5-HT(2A/2C) receptor antagonist ketanserin (2 mg/kg), or the 5-HT(7) receptor antagonist SB-269970 (10 mg/kg). Apomorphine-induced disruptions of PPI were reversed by haloperidol and SCH 23390 only. Estrogen may prevent disruptions of PPI induced by both 8-OH-DPAT and apomorphine by an action on dopamine D(2) receptors downstream of 5-HT(1A) receptors. SN - 1521-0103 UR - https://www.unboundmedicine.com/medline/citation/20042529/Estrogen_treatment_blocks_8_hydroxy_2_dipropylaminotetralin__and_apomorphine_induced_disruptions_of_prepulse_inhibition:_involvement_of_dopamine_D1_or_D2_or_serotonin_5_HT1A_5_HT2A_or_5_HT7_receptors_ DB - PRIME DP - Unbound Medicine ER -